Clinical Trials
18 trialsNCT00720785 2026-05-07
Natural Killer Cells and Bortezomib to Treat Cancer
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT01833143 2020-08-04
Bortezomib in KRAS-Mutant Non-Small Cell Lung Cancer in Never Smokers or Those With KRAS G12D
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00064012 2019-12-13
Bortezomib With or Without Docetaxel in Treating Patients With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer
University of Wisconsin, Madison
Phase 2 Completed
NCT00798720 2019-12-13
Vorinostat and Bortezomib as Third-line Treatment in Advanced Non-small Cell Lung Cancer
University of Wisconsin, Madison
Phase 2 Completed
NCT00389805 2018-10-31
Bortezomib and Pemetrexed Disodium in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors
University of California, Davis
Phase 1/2 Completed
NCT00093756 2017-12-07
Bortezomib, Paclitaxel, Carboplatin and Radiation Therapy for Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00362882 2017-12-05
Docetaxel and Bortezomib in Treating Patients With Progressive or Recurrent Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00622674 2017-12-02
Bortezomib and Cetuximab in Treating Patients With Advanced Solid Tumors
Masonic Cancer Center, University of Minnesota
Phase 1 Completed
NCT00620295 2017-11-29
Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid Tumors
Masonic Cancer Center, University of Minnesota
Phase 1 Completed
NCT00731952 2017-05-04
Phase I Study of Induction Therapy With VELCADE and Vorinostat in Patients With Surgically Resectable Non-Small Cell Lung Cancer
University of Virginia
Phase 1 Completed
NCT01633645 2015-09-28
Bortezomib in Combination With Gemcitabine and Cisplatin in Advanced or Metastatic Non-Small Cell Lung Cancer
University Hospital of Crete
Phase 2 Completed
NCT00118144 2014-08-21
Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00118183 2013-06-04
Docetaxel With Either Cetuximab or Bortezomib as First-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00075751 2013-02-28
Gemcitabine, Carboplatin, and Bortezomib in Advanced or Recurrent Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00052338 2013-01-23
Bortezomib Plus Gemcitabine and Carboplatin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT00667641 2011-05-10
Paclitaxel and Bortezomib in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors
Rutgers, The State University of New Jersey
Phase 1 Completed
NCT00343720 2008-03-13
Study of Alimta® (Pemetrexed) Plus VELCADE® (Bortezomib) or Alimta Alone or VELCADE Alone in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Prior Therapy
Millennium Pharmaceuticals, Inc.
Phase 2 Completed
NCT00051974 2008-02-11
Phase 2 Study of VELCADE Alone or VELCADE® Plus Docetaxel in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer
Millennium Pharmaceuticals, Inc.
Phase 2 Completed